Development of a lung METAstasis-on-a-CHIP model for osteosarcoma as a biomimeti...
Development of a lung METAstasis-on-a-CHIP model for osteosarcoma as a biomimetic testing platform for drug discovery and therapeutic innovation
Osteosarcoma is a highly aggressive bone cancer that primarily affects children. Secondary lung metastasis is the most critical clinical factor, with 70% of those who develop lung metastasis succumbing to the disease within 3 year...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SkinModelOma
Multicompartment combinatory pre-clinical model for melanoma...
173K€
Cerrado
MiTuMi
Bioengineered Matrices Mimicking the Lung Tumor Microenviron...
145K€
Cerrado
PID2019-106099RB-C43
DESARROLLO DE ANDAMIAJES BIOMIMETICOS ACTIVOS PARA EL ESTUDI...
182K€
Cerrado
RTC2019-007067-1
Identificación de biomarcadores clínicos de respuesta a la i...
1K€
Cerrado
B2B
Modeling spontaneous Breast cancer metastasis TO the Bone wi...
4M€
Cerrado
CombaTCancer
Rational combination therapies for metastatic cancer
2M€
Cerrado
Información proyecto META-CHIP
Duración del proyecto: 59 meses
Fecha Inicio: 2024-09-01
Fecha Fin: 2029-08-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Osteosarcoma is a highly aggressive bone cancer that primarily affects children. Secondary lung metastasis is the most critical clinical factor, with 70% of those who develop lung metastasis succumbing to the disease within 3 years. Despite the resonating clinical urgency for newer, more effective treatment options, there have been no changes in treatment since the introduction of chemotherapy in the 1970s. Furthermore, osteosarcoma is a rare disease making the conduct of large clinical trials investigating novel therapies very challenging. META-CHIP proposes to embark upon frontier research by being the first to develop a lung metastasis-on-a-chip model for osteosarcoma, for use by both the research community and the pharmaceutical industry. This will be realized by first testing the hypothesis that patient derived tumour spheroids (PDTS) generated from patient biopsies will recapitulate the primary tumour and thus be a superior drug development model than traditional cell culture models (Aim 1). An osteosarcoma-on-a-chip device will be developed integrating PDTS, microfluidic technology, and novel biomaterial design to provide a more accurate model of the tumour microenvironment (Aim 2). To validate the device, the ability to predict clinical outcomes on tumour growth following treatment with two anti-angiogenic drugs, which have progressed to Phase II clinical trials will be assessed (Aim 3). Finally, META-CHIP will develop a much-needed platform which mimics key aspects of osteosarcoma metastatic disease progression to the lung. This will be achieved through functional-coupling of the osteosarcoma-on-a-chip device with an established lung-chip to create a medium-throughput, cost-effective, human systemic model of osteosarcoma metastasis (Aim 4). META-CHIP has the potential to revolutionise drug development and treatment of osteosarcoma patients by being the first ex vivo testing platform capable of predicting a patient’s response to therapies in real-time.